Skip to content

Based on the theory of inflammatory response regulation of bone remodeling homeostasis, this study aims to investigate the clinical efficacy and mechanism of "Lumu Analgesic Decoction" in treating blood stasis-type osteoporotic pain.

Based on the theory of inflammatory response regulation of bone remodeling homeostasis, this study aims to investigate the clinical efficacy and mechanism of "Lumu Analgesic Decoction" in treating blood stasis-type osteoporotic pain.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000740
Enrollment
Unknown
Registered
2026-03-25
Start date
2025-09-12
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Stasis Type Osteoporosis-related Pain

Interventions

Control Group:Routine intervention
Observation group:Routine intervention + Liumo Analgesic Beverage

Sponsors

Xi'an City Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Agree to participate in this clinical trial and sign the informed consent form; 2. Meet the Western diagnostic criteria for primary osteoporosis; 3. Be diagnosed with blood stasis syndrome according to traditional Chinese medicine; 4. All patients have pain in the waist, back, or joint areas, with a pain duration of =3 months.

Exclusion criteria

Exclusion criteria: 1. Individuals who have experienced a fracture within the past six months 2. Those with concurrent endocrine or metabolic disorders (hyperparathyroidism, Cushing's syndrome, hyperthyroidism, hypergonadism, diabetes), hematologic disorders (myeloma, leukemia), severe gastrointestinal diseases, and mental or neurological disorders, etc 3. ; 4. Individuals with severe cardiovascular diseases or impaired liver or kidney function 5. Patients with mental disorders 6. Those participating in other clinical trials or who have completed participation in other drug clinical trials within the past three months

Design outcomes

Primary

MeasureTime frame
Bone Density Measurement;Pain score;Bone turnover markers: ß-CTX, PINP;Inflammatory factors: TNF-alpha, IL-1;

Secondary

MeasureTime frame
Blood Stasis Syndrome Scoring;Serum MCV, RDW-CV, MPV, PDW;

Countries

China

Contacts

Public ContactWang Hui

Xi'an City Traditional Chinese Medicine Hospital

11564757@qq.com18092071913

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026